Zevra Therapeutics (ZVRA) Non Operating Income (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Non Operating Income of -$7.3 million for Q1 2026, down 319.1% on a QoQ basis from $3.4 million in Q4 2025, and down 313.12% year-over-year from $3.4 million in Q1 2025.
Zevra Therapeutics (ZVRA) Non Operating Income (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Non Operating Income history runs 13 years deep, the most recent figure standing at -$7.3 million for Q1 2026.
- Quarterly Non Operating Income fell 313.12% year-over-year to -$7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.8 million (up 4082.62% YoY) and the FY2025 annual result came in at $149.6 million, up 4869.56% from the prior year.
- Non Operating Income was -$7.3 million for Q1 2026 at Zevra Therapeutics, down from $3.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $147.9 million in Q2 2025 and bottomed at -$7.3 million in Q1 2026.
- A 5-year average of $9.6 million and a median of $3.4 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 22595.65% — and 2026, when it plunged 313.12%.
- Zevra Therapeutics' Non Operating Income stood at $6.1 million in 2022, then sank by 177.45% to -$4.7 million in 2023, then retreated by 4.58% to -$5.0 million in 2024, then jumped by 167.67% to $3.4 million in 2025, then slumped by 319.1% to -$7.3 million in 2026.
- Business Quant data shows ZVRA's Non Operating Income at -$7.3 million in Q1 2026, $3.4 million in Q4 2025, and -$5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | -7.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.34 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | 147.95 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | -4.95 Mn |
| Sep 30, 2024 | -5.92 Mn |
| Jun 30, 2024 | 3.94 Mn |
| Mar 31, 2024 | 3.79 Mn |
| Dec 31, 2023 | -4.74 Mn |
| Sep 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 3.61 Mn |
| Mar 31, 2023 | -489,000.00 |
| Dec 31, 2022 | 6.11 Mn |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | 2.88 Mn |
| Mar 31, 2022 | 12.35 Mn |
| Dec 31, 2021 | 173,000.00 |
| Sep 30, 2021 | 463,000.00 |
| Jun 30, 2021 | 370,000.00 |